Sign InJohnson & Johnson Exceeds Expectations in Q2, Boosts Full-Year Outlook
Alex Vellor
Johnson & Johnson (NYSE: JNJ) reported strong Q2 results, surpassing Wall Street estimates in both earnings and revenue.
The healthcare giant posted an adjusted earnings per share (EPS) of $2.82, beating analysts' predictions by $0.10. Revenue reached $22.45 billion, topping the consensus estimate of $22.34 billion. This performance marks a 4.3% increase in reported sales growth, with an operational growth of 6.6%.
The stock responded positively, with shares rising 2.1% as investors reacted to the earnings and revenue beat. Despite a 5.9% decrease in reported EPS due to one-time charges, adjusted EPS saw a significant increase of 10.2%.
Key financial results for Q2:
| Metric | Result |
| Adjusted EPS | $2.82 |
| Analyst EPS Prediction | $2.72 |
| Revenue | $22.45 billion |
| Analyst Revenue Prediction | $22.34 billion |
| Reported Sales Growth | 4.3% |
| Operational Growth | 6.6% |
| Operational Sales Growth (ex. COVID) | 7.1% |
| Stock Price Increase | 2.1% |
| Full-Year EPS Guidance | $10.05 |
| Analyst Full-Year EPS Consensus | $10.01 |
The MedTech segment grew, with a 4.4% increase in worldwide operational sales, particularly in electrophysiology and wound closure products.
Looking ahead, Johnson & Johnson raised its full-year operational sales guidance and updated its adjusted operational EPS guidance, now anticipating a full-year EPS of $10.05, slightly above analysts' consensus of $10.01. CEO Joaquin Duato expressed confidence in the company's future, highlighting its robust pipeline and strategic acquisitions as foundations for continued growth.
About The Author
Alex Vellor
Read Next in Latest Stock Market News
